The phase 1 trial was investigating a CAR-T gene therapy called P-PSMA-101, designed to treat prostate cancer.
The patient had metastatic castrate-resistant prostate cancer and died of liver failure 19 days after receiving the CAR-T treatment. He had missed two follow-up visits and developed symptoms that led to him being hospitalized, according to the SEC filing.
Poseida is waiting on a formal response from the FDA and preparing recommendations to allow the trial to resume, the drugmaker said.
The drugmaker’s shares fell 35 percent after the announcement.
More articles on pharmacy:
CVS partnering with Delta Air Lines for rapid COVID-19 testing program
Sanofi inks $3.68B deal to buy California autoimmune drugmaker
US to test benefits of remdesivir with second drug
